LONDON - Genflow Biosciences Plc (LSE:GNF) (OTCQB:GENFF), a biotechnology company specializing in longevity research, has announced the commencement of two research programs focused on ageing, backed by government grants from Wallonia, Belgium. The grants, part of the Wallonia Recovery Plan, aim to advance therapeutic solutions for age-related conditions.
The first program, a collaboration with Revatis SA, has received 1.34 million euros for sarcopenia research. This three-year initiative will explore the progressive loss of muscle mass and strength that occurs with ageing, a condition affecting many elderly individuals globally. The partnership will combine Genflow's and Revatis SA's expertise to investigate the mechanisms behind muscle deterioration in older adults.
The second program, in partnership with EXO Biologics, is supported by a grant of 1.55 million euros and will span over three years. It focuses on the development of a novel mRNA delivery system using exosomes. The goal is to encapsulate and transport Genflow's proprietary centenarian SIRT6 gene, potentially offering a breakthrough in treating Werner Syndrome, an accelerated ageing condition, and possibly other age-related diseases.
Both research programs are part of a broader initiative by the Walloon Government, dedicated to Advanced Therapy Medicinal Products (ATMPs), with a budget of 81 million euros over three years. This initiative represents a mix of public and private funding and involves BioWin, the Health Cluster of Wallonia, and the Public Service of Wallonia.
Dr. Eric Leire, CEO of Genflow, expressed enthusiasm about the new research endeavors, highlighting the strategic move to enhance the company's research capabilities and contribute to the understanding of age-related conditions.
Genflow Biosciences, established in 2020 and based in the UK with R&D facilities in Belgium, is developing novel therapeutics aimed at halting or slowing the ageing process. The company's lead compound, GF-1002, has shown promising preclinical results and is expected to enter clinical trials in 2024 for non-alcoholic steatohepatitis (NASH).
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.